Kiniksa Pharmaceuticals (KNSA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Eva Fortea Verdejo from Wells Fargo maintained a Buy rating on the stock and has a $30.00 price target.
Eva Fortea Verdejo has given her Buy rating due to a combination of factors that highlight Kiniksa Pharmaceuticals’ potential for growth and stability. Despite the unexpected discontinuation of abiprubart, the company’s new pipeline assets, particularly in the cardiovascular domain, are seen as promising. The focus on recurrent pericarditis and the collaboration in cardiac sarcoidosis are expected to drive growth, with Arcalyst revenues providing a stable outlook for 2025.
Additionally, the development of KPL-387 with its monthly dosing capability and full ownership by Kiniksa is viewed as a significant advantage, potentially enhancing market penetration. The strategic decision to discontinue abiprubart aligns with the company’s focus on cardiovascular advancements, and the introduction of KPL-1161 offers further opportunities in this field. These factors, combined with adjustments in the financial model and a positive outlook on market opportunities, underpin the Buy rating.
Fortea Verdejo covers the Healthcare sector, focusing on stocks such as Kiniksa Pharmaceuticals, Xencor, and Merus. According to TipRanks, Fortea Verdejo has an average return of -18.9% and a 25.00% success rate on recommended stocks.